Research at Vanderbilt University has led to the identification of new muscarinic M5 receptor antagonists reported to be useful for the treatment of psychiatric disorders.
Nerio Therapeutics Inc. has patented new tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and/or tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) inhibitors reported to be useful for the treatment of cancer, diabetes type 2, obesity and metabolic diseases.
C4x Discovery Holdings plc has prepared and tested mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors. As such, they are reported to be useful for the treatment of cancer, asthma, gout and psoriasis, among others.
Eikonizo Therapeutics Inc. has described histone deacetylase 6 (HDAC6) inhibitors reported to be useful for the treatment of cancer, multiple sclerosis, systemic lupus erythematosus, neurodegeneration, obesity, Alzheimer’s disease, Parkinson’s disease and Huntington’s disease, among others.
Janssen Pharmaceutica NV has divulged pyrazolopyrimidines acting as spermine oxidase (polyamine oxidase 1; SMOX) inhibitors reported to be useful for the treatment of colorectal cancer.
Merck Sharp & Dohme Corp. has synthesized plasma kallikrein (KLKB1) inhibitors reported to be useful for the treatment of hereditary angioedema, diabetic macular edema, retinal vein occlusion, diabetic retinopathy, wet macular degeneration (exudative) and uveitis.
Researchers at Jiangsu Hengrui Medicine Co. Ltd., Shanghai Senhui Pharmaceutical Co. Ltd. and Shanghai Shengdi Pharmaceutical Co. Ltd. have disclosed antibody-drug conjugates (ADCs) comprising monoclonal antibodies targeting IL-4R covalently linked to glucocorticoid analogues through a linker. They are reported to be useful for the treatment of asthma and skin allergy.
RSS
